Evidence map›Paper›PMID 40746343›Full record

ArticleJHLT open2025

Ex situ heart perfusion: A novel platform to test cardiovascular therapeutics in human hearts.

John Onsy Louca, Magnus Althage, Marco Öchsner, Aravinda Page, Joao Pedro Nunes, Catherine Wilson, Sanjay Sinha, Simon Messer, James Matt Bae, Mostin Hu and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. mRNA medicine for cardiovascular disease.Nature cardiovascular research · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

John Onsy LoucaJeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, The University of Cambridge, Cambridge, Cambridgeshire, UK.
Magnus AlthageTranslational Science & Experimental Medicine Department, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Marco ÖchsnerDepartment of Medicine, The University of Cambridge, Cambridge, Cambridgeshire, UK.
Aravinda PageRoyal Papworth Hospital, Cambridge, Cambridgeshire, UK.
Joao Pedro NunesRoyal Papworth Hospital, Cambridge, Cambridgeshire, UK.
Catherine WilsonDepartment of Pharmacology; The University of Cambridge, Cambridgeshire, UK.
Sanjay SinhaJeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, The University of Cambridge, Cambridge, Cambridgeshire, UK.
Simon MesserRoyal Papworth Hospital, Cambridge, Cambridgeshire, UK.
James Matt BaeDepartment of Medicine, The University of Cambridge, Cambridge, Cambridgeshire, UK.
Mostin HuDepartment of Medicine, The University of Cambridge, Cambridge, Cambridgeshire, UK.
Nicole AsemotaRoyal Papworth Hospital, Cambridge, Cambridgeshire, UK.
Sarah FieldingRoyal Papworth Hospital, Cambridge, Cambridgeshire, UK.
Sai BhagraRoyal Papworth Hospital, Cambridge, Cambridgeshire, UK.
Neil HendersonIntegrated Bioanalysis Department, Clinical Pharmacology & Safety Sciences, AstraZeneca, Gothenburg, Sweden.
Johnny LindquistIntegrated Bioanalysis Department, Clinical Pharmacology & Safety Sciences, AstraZeneca, Gothenburg, Sweden.
Daniela SpäterBioscience Cardiovascular Department, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Anna CollénResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Kaushik SenguptaAlliance Management, Business Development and Licensing, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Benjamin ChallisTranslational Science & Experimental Medicine Department, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Justin PerkinsRoyal Veterinary College, Hertfordshire UK.
Stephen LargeRoyal Papworth Hospital, Cambridge, Cambridgeshire, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Explanted hearts from recipients undergoing cardiac transplantation may be utilized as a human model of cardiomyopathy. Ex-situ perfusion of hearts allows control of the physiological and biochemical conditions of perfusion. Methods: In order to ascertain the expression of VEGF-A in a human model of cardiomyopathy, Results: There were elevated levels of VEGF-A protein in the subendocardium and mid-myocardium of injection sites which received Conclusions: This study builds on the EPICCURE study, a phase IIa clinical trial which demonstrated safety of this mRNA in patients undergoing coronary artery bypass grafting. This study provides a novel model of diseased human heart for experimental studies utilizing ex situ heart perfusion.

Indexed as

Angiogenesis, mRNA therapies, Vascular endothelial growth factor-ACardiomyopathyDrug discoveryEx-Situ Heart PerfusionHuman model of heart failure

Identifiers

PMID40746343
PMCPMC12310391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.